

MELOXICAM, meloxicam tablet
INDICATIONS AND USAGE

BRIEF SUMMARY OF PRESCRIBING INFORMATION

This highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.

MELOXICAM tablets, for oral use

Initial U.S. Approval: 2009

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
See full prescribing information for complete boxed warning.

- **Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [1, 2].**
- **Meloxicam is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [4, 5].**
- **NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including ulceration, perforation and obstruction of the stomach or intestine, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of GI bleeding are at greater risk for serious GI events [3].**

RECENT MAJOR CHANGES

Indications and Usage: Juvenile Rheumatoid Arthritis (RA)	02/10
Preclinical and Polymeric Content (1.2)	02/10
Design and Administration: Juvenile Rheumatoid Arthritis (RA)	02/10
Preclinical and Polymeric Content (2.4)	02/10
Warnings and Precautions: Cardiovascular Thrombotic Events (1.1)	02/10
Warnings and Precautions: Gastrointestinal Thrombotic Events (1.2)	02/10
Warnings and Precautions: Bleeding and Hemorrhage (1.3)	02/10

INDICATIONS AND USAGE

Meloxicam is a nonsteroidal anti-inflammatory drug indicated for:

- Osteoarthritis (OA) [1, 2]
- Rheumatoid Arthritis (RA) [1, 2]
- Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg [1, 3]

DOSEAGE AND ADMINISTRATION

Use the lowest effective dose for the shortest duration consistent with individual patient's condition.

- **Adults:** Starting dose: 7.5 mg once daily
- There may be increased risk if taken more than once daily
- **RA (2.4):** 7.5 mg once daily in children ≥60 kg
- **7.5 mg once daily in children ≥60 kg**
- Meloxicam tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same [1, 2]

CONTRAINDICATIONS

- Known hypersensitivity to meloxicam or any components of the drug product [4]
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs [4]
- In the setting of CABG surgery [4]

WARNINGS AND PRECAUTIONS

- **Cardiovascular Thrombotic Events:** Inhibits platelet aggregation and increases risk of thrombotic events. Discontinue if abnormal heart rates occur or if clinical signs and symptoms of heart disease develop [1, 2].
- **Gastrointestinal Thrombotic Events:** Patients taking some antiplatelet/anticoagulant medications may have impaired response to these therapies [See Warnings and Precautions (1.3)].
- **GI Bleeding, Ulceration, Perforation, and Obstruction:** Avoid use of meloxicam in patients with severe heart failure unless benefits are expected to outweigh the risk. Monitor fluid balance in patients with renal or hepatic impairment. Do not use in patients with severe heart failure.
- **Hypertension:** Avoid use of meloxicam in patients with advanced or end-stage disease unless benefits are expected to outweigh the risk of worsening hypertension [1, 2].
- **Renal Impairment:** Seek appropriate help if anaphylactoid reaction occurs [5, 7].
- **Cardiovascular Risk:** Meloxicam is contraindicated in patients with angiotensin-converting enzyme inhibitor patients with pre-existing asthma (unless aspirin sensitive) [1, 2].
- **Renal Impairment:** Decrease meloxicam at first appearance of renal dysfunction or signs of hypotension [1, 2].
- **Preclinical and Polymeric Content:** Avoid use in pregnant women starting at 30 weeks gestation [1, 2].
- **Renal Impairment:** Monitor renal function in patients with any signs or symptoms of renal dysfunction [1, 2].

ADVERSE REACTIONS

- Most common (≥5% and greater than placebo): adverse events in adults are diarrhea, upper respiratory tract infection, dyspepsia, and influenza-like symptoms [6].
- Adverse events observed in pediatric studies were similar to those in the adult clinical trial population [6].

See full prescribing information for complete list of adverse reactions.

DRUG INTERACTIONS

- **Other NSAIDs:** Concurrent use with other NSAIDs, salicylates, or aspirin may increase the risk of gastrointestinal bleeding.
- **Aspirin:** Concurrent use with aspirin may increase the risk of gastrointestinal bleeding.
- **Anticoagulants:** Concurrent use with anticoagulants may increase the risk of bleeding.
- **Antidiabetic Agents:** Concurrent use with antidiabetic agents may increase the risk of hypoglycemia.
- **Antihypertensives:** Concurrent use with antihypertensives may increase the risk of hypotension.
- **Anticholinergics:** Concurrent use with anticholinergics may increase the risk of urinary retention.
- **Antacids:** Concurrent use with antacids may decrease the absorption of meloxicam.
- **Alcohol:** Concurrent use with alcohol may increase the risk of gastrointestinal bleeding.
- **Other Drugs:** Concurrent use with other drugs may increase the risk of adverse events.

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

HOW SUPPLIED

Meloxicam tablets are available in the following strengths and packaging:

- 7.5 mg (white) tablets, 15 tablets per bottle
- 15 mg (yellow) tablets, 15 tablets per bottle

Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (3.7, 5.B)]

- In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.D)]

5 WARNINGS AND PRECAUTIONS

5.1 Cardiovascular Thrombotic Events

A meta-analysis of several COX-2 selective and nonselective NSAIDs of up to three years duration has shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk of CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events may have been conferred by NSAID use compared to placebo. There is also concern that the relative increase in serious CV thrombotic events may differ between patients with and without known disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of serious CV thrombotic events, due to their increased baseline risk. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most prominently at higher doses.

To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as celecoxib, increases the risk of serious gastrointestinal (GI) events [see Warnings and Precautions (2.7)].

5.2 Postoperative Myocardial Infarction and Stroke

Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [see Contraindications (4)].

5.3 MI Events

Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 persons in NSAID-treated patients compared to 12 per 100 persons in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

Avoid the use of meloxicam in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If meloxicam is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

5.2 Gastrointestinal Bleeding, Ulceration, and Perforation

NSAIDs, including meloxicam, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, and large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI adverse events include bleeding and perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. However, even shorter-term NSAID therapy is associated with risk.

5.2 Factors that Increase the Risk of GI Bleeding, Ulceration, and Perforation

Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing an upper GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most gastrointestinal events of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.

5.2 Strategies to Minimize the GI Risk in NSAID-Treated Patients

- Use the lowest effective dosage for the shortest possible duration.
- Avoid administration of any other NSAID at the same time.
- Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs.
- Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.
- If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue meloxicam until a serious GI adverse event is ruled out.
- Avoid concurrent use of low-dose aspirin for cardiac prophylaxis; monitor patients more closely for evidence of GI bleeding [see Drug Interactions (7)].

5.3 Hepatotoxicity

Elevation of ALT or AST (three or more times the upper limit of normal [ULN]) has been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatic liver necrosis, and hepatic failure have been reported.

Elevation of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including meloxicam.

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue meloxicam immediately, and perform a clinical evaluation of the patient [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

5.4 Hypertension

NSAIDs, including meloxicam, can lead to new onset or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, diuretic diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [see Drug Interactions (7)].

Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.

5.5 Heart Failure and Edema

The Coxs and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials found an increase in approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of meloxicam may mask the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [see Drug Interactions (7)].

Avoid the use of meloxicam in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If meloxicam is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

5.6 Renal Toxicity and Hyperkalemia

5.6.1 Renal Toxicity

Long-term administration of NSAIDs, including meloxicam, has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury.

Renal toxicity may also be seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation, which can result in renal failure, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypotension, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

The renal effects of meloxicam may lessen the progression of renal dysfunction in patients with preexisting renal disease. Because some meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function.

Correct volume status in dehydrated or hypovolemic patients prior to initiating meloxicam. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of meloxicam [see Drug Interactions (7)].

No information is available from controlled clinical studies regarding the use of meloxicam in patients with advanced renal disease. Avoid the use of meloxicam in patients with advanced disease unless the benefits are expected to outweigh the risk of worsening renal function. If meloxicam is used in patients with advanced renal disease, monitor patients for signs of worsening renal function [see Clinical Pharmacology (12.3)].

5.6.2 Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic, hypoadrenergic state.

5.7 Anaphylactic Reactions

Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma [see Contraindications (4) and Warnings and Precautions (5.B)].

Seek emergency help if an anaphylactic reaction occurs.

5.8 Case Reports of Asthma Related to Aspirin Sensitivity

A subgroup of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe, potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, meloxicam is contraindicated in patients with this form of aspirin sensitivity [see Contraindications (4)]. When meloxicam is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.

5.9 Serious Skin Reactions

NSAIDs, including meloxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and the importance of the use of meloxicam in the event appearance of skin rash or any other signs of hypersensitivity. Meloxicam is contraindicated in patients with previous serious skin reactions to NSAIDs [see Contraindications (4)].

5.10 Premature Closure of Fetal Ductus Arteriosus

Meloxicam may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including meloxicam, in pregnant women starting at 30 weeks of gestation (third trimester) [see Use in Specific Populations (8.1)].

5.11 Hematologic Toxicity

Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an idiosyncratic decreased effect on erythropoiesis. If a patient treated with meloxicam has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including meloxicam, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concurrent use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin, acetaminophen, salicylates, SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].

5.12 Masking of Inflammation and Fever

The pharmacological activity of meloxicam in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infection.

5.13 Laboratory Monitoring

Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [see Warnings and Precautions (5.2, 5.3, 5.6)].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Cardiovascular Thrombotic Events [see Blood Warning and Warnings and Precautions (5.1)]
- GI Bleeding, Ulceration, and Perforation [see Blood Warning and Warnings and Precautions (5.2)]
- Hypertension [see Warnings and Precautions (5.3)]
- Hypersensitivity [see Warnings and Precautions (5.4)]
- Heart Failure and Edema [see Warnings and Precautions (5.5)]
- Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.6)]
- Anaphylactic Reactions [see Warnings and Precautions (5.7)]
- Serious Skin Reactions [see Warnings and Precautions (5.9)]
- Hematologic Toxicity [see Warnings and Precautions (5.11)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1.1 Adults

6.1.1.1 Osteoarthritis and Rheumatoid Arthritis

The meloxicam Phase 2b clinical trial database includes 10,122 OA patients and 1012 RA patients treated with meloxicam 7.5 mg/day, 1505 OA patients and 1331 RA patients treated with meloxicam 15 mg/day. Meloxicam in these doses was administered to 651 patients in at least one study and to 312 patients for at least one year. Approximately 10,500 of these patients were treated in two placebo- and/or active-controlled osteoarthritis trials and 2983 of these patients were treated in two placebo- and/or active-controlled rheumatoid arthritis trials. Co-morbidity (CM) adverse events were the most frequently reported adverse events in all treatment groups across meloxicam trials.

A 12-week meloxicam, double-blind, randomized trial was conducted in patients with osteoarthritis of the knee to compare the efficacy and safety of meloxicam with placebo and with an active control. Two 12-week meloxicam, double-blind, randomized trials were conducted in patients with rheumatoid arthritis to compare the efficacy and safety of meloxicam with placebo.

Table 1a depicts adverse events that occurred in ≥2% of the meloxicam treatment groups in a 12-week placebo- and active-controlled osteoarthritis trial.

Table 1b depicts adverse events that occurred in ≥2% of the meloxicam treatment groups in two 12-week placebo-controlled rheumatoid arthritis trials.

Table 1a: Adverse Events (%) Occurring in ≥ 2% of Meloxicam Patients in a 12-Week Osteoarthritis Placebo- and Active-Controlled Trial

No. of Patients	Placebo		Meloxicam		Diclofenac	
	7.5 mg daily	15 mg daily	7.5 mg daily	15 mg daily	150 mg daily	150 mg daily
GI/upper abdominal pain	1.7	2.1	1.7	2.1	2.1	2.1
Abdominal pain	2.5	1.9	2.6	1.3		
Diarrhea	3.8	7.8	3.2	9.2		

Risk Summary

There are no human data available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for meloxicam and any potential adverse effects on the breastfed infant from the meloxicam or from the underlying medical condition.

Data

Animal data

Meloxicam was present in the milk of lactating rats at concentrations higher than those in plasma.

8.3 Females and Males of Reproductive Potential

Females

Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including meloxicam, may delay or prevent ovulation of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthase inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown reversible delay in ovulation. Consider withdrawal of NSAIDs, including meloxicam, in women who have difficulties conceiving or who are undergoing investigation of infertility.

8.4 Pediatric Use

The safety and effectiveness of meloxicam in pediatric JRA patients from 3 to 17 years of age has been evaluated in three clinical trials. [see Dosage and Administration (2.3), Adverse Reactions (4.1) and Clinical Studies (14.2)]

8.5 Geriatric Use

Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.13)]

8.6 Hepatic Impairment

No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment have not been adequately studied. Since meloxicam is significantly metabolized in the liver and hepatotoxicity may occur, use meloxicam with caution in patients with hepatic impairment [see Warnings and Precautions (5.3) and Clinical Pharmacology (2.3)]

8.7 Renal Impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of meloxicam in subjects with severe renal impairment is not recommended. In patients on hemodialysis, meloxicam should not exceed 7.5 mg per day. Meloxicam is not dialyzable [see Dosage and Administration (2.3) and Clinical Pharmacology (2.3)]

10 OVERDOSAGE

Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [see Warnings and Precautions (5.1, 5.2, 5.4, 5.6)]


Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 g in adults, 10 to 2 gram per kg of body weight in pediatric patients) within 1-2 hours of ingestion. Gastric lavage may be useful within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may be useful due to high protein binding.

There is limited experience with meloxicam overdosage. Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage.

For additional information about overdosage treatment, call a poison control center (1-800-222-1222).

11 DESCRIPTION

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID). Each tablet contains 7.5 mg or 15 mg meloxicam USP for oral administration. Meloxicam is chemically designated as 4-methoxy-2-methyl-5-(methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C₁₄H₁₃N₃O₄S₂ and it has the following structural formula:



Meloxicam is a pale yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)_{app} = 0.1 in a 0.1M sodium buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2.

Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam, USP. The inactive ingredients in meloxicam tablets, USP include starch, microcrystalline cellulose, lactose anhydrous, colloidal silicon dioxide, sodium croscarmellose, dibutyltin dilaurate, magnesium stearate.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Meloxicam is a potent inhibitor of prostaglandin synthesis *in vitro*. Meloxicam concentrations reached during therapy have produced *in vivo* effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandin in peripheral tissues.

12.3 Pharmacokinetics

Absorption

The absolute bioavailability of meloxicam capsules was 89% following a single oral dose of 30 mg compared with 30 mg IV bolus injection. Following single intravenous doses, dose-proportional pharmacokinetics were shown in the range of 5 mg to 60 mg. After multiple oral doses the pharmacokinetics of meloxicam capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean C_{max} was achieved within four to five hours after a 7.5 mg meloxicam tablet was taken under fasted conditions, indicating a prolonged drug absorption. With multiple dosing, steady-state concentrations were reached by Day 5. A second meloxicam concentration peak occurs around 12 to 14 hours post-dose suggesting biliary recycling. Meloxicam capsules have been shown to be bioequivalent to meloxicam tablets.

Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)¹

Pharmacokinetic Parameters (% CV)	Steady State		Single Dose	
	Healthy male adults (F=0) ²	Elderly males (F=0) ²	Female adults (F=100) ³	Elderly females (F=100) ³
N	18	6	6	12
t_{max} (h)	2.1 (20)	2.1 (20)	3.2 (24)	0.6 (6)
t_{1/2} (h)	4.9 (23)	5.1 (23)	4.0 (20)	15 (23)
t_{1/2} (h)	20 (29)	21 (34)	24 (34)	18 (45)
C_{max} (ng/mL)	8.8 (29)	8.9 (29)	14 (22)	19 (43)
AUC₀₋₂₄ (h·ng/mL)	14.2 (32)	15 (42)	10 (30)	20 (44)

¹See parentheses values in the tables for mean versus standard.

²Fast under high fat conditions.

³Fast under high fat conditions.

⁴y = 1 + 0.01x (AUC-0-24)

Food and Absorption Effects

Administration of meloxicam capsules following a high fat breakfast (75 % of fat) resulted in mean peak drug levels (i.e., C_{max}) being increased by approximately 22%, while the extent of absorption (AUC) was unchanged. The time to maximum concentration (t_{max}) was achieved between 5 and 6 hours. In comparison, neither the AUC nor the C_{max} values for meloxicam capsules were affected following a single high fat meal, while mean t_{max} values were increased to approximately 7 hours. No pharmacokinetic interaction was detected with concurrent administration of meals. Based on these results, meloxicam can be administered without regard to timing of meals or concurrent administration of meals.

Distribution

The mean volume of distribution (V_d) of meloxicam is approximately 10 L. Meloxicam is ~99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to ~95% in patients with renal disease. Meloxicam penetrates into human red blood cells, after oral dosing, is less than 10%. Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam.

Meloxicam concentration in synovial fluid, after a single oral dose, range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid as compared to plasma. The significance of this penetration is unknown.

Elimination

Metabolism

Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 5-carboxy meloxicam (60% of dose), from P-450 mediated metabolism formed by oxidation of an imine-methoxy 5-hydroxymethyl meloxicam which is also excreted to a lesser extent (4% of dose). In two studies indicate that CYP2C9 (cytochrome P450 metabolizing enzyme) plays an important role in this metabolic pathway with a minor contribution of the CYP2C8 isozyme. Potent peroxylase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose, respectively. All the four metabolites are not known to have any *in vivo* pharmacological activity.

Excretion

Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extent in the urine and feces. Only traces of the unchanged parent compound are excreted in urine (0.2%) and feces (1.4%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.2%, 6%, and 13% of the dose were found in urine in the form of meloxicam, and the 5-hydroxymethyl and 5-carboxy metabolites, respectively. There is significant biliary and/or renal excretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%.

The mean elimination half-life (t_{1/2}) ranges from 15 hours to 30 hours. The elimination half-life is constant across dose levels indicating linear metabolism within the therapeutic dose range. Plasma clearance ranges from 7 to 9 mL/min.

Specific Populations

Pediatric

After single (0.25 mg/kg) dose administration and after achieving steady state (0.375 mg/kg/day), there was a general trend of approximately 30% lower exposure in younger patients (2 to 6 years old) as compared to older patients (7 to 16 years old). The older patients had meloxicam exposure similar (single dose) or slightly reduced (steady state) those in the adult patients, when using AUC values normalized to a dose of 0.1 mg/kg [see Dosage and Administration (2.3)]. The meloxicam mean oral elimination half-life was 15.2 (0.3) and 13.1 hours (0.3) for the 2 to 6 year old patients, and 7 to 16 year old patients, respectively.

In a covariate analysis, utilizing population pharmacokinetics body-weight, but not age, was the single predictive covariate for differences in the meloxicam apparent oral plasma clearance. The body-weight normalized apparent oral clearance values were adequate predictors of meloxicam exposure in pediatric patients.

The pharmacokinetics of meloxicam in pediatric patients under 2 years of age have not been investigated.

Geriatric

Elderly males (65 years of age) exhibited meloxicam plasma concentrations and steady-state pharmacokinetics similar to young males. Elderly females (65 years of age) had 4.4% higher AUC and 20% higher C_{max} as compared to younger females (55 years of age) after body weight normalization. Despite the increased total concentrations in the elderly females, the adverse effect profile was comparable to both elderly patient populations. A similar free fraction was found in elderly female patients in comparison to elderly male patients.

Sex

Young females exhibited slightly lower plasma exposure doses relative to young males. After single doses of 7.5 mg meloxicam, the mean elimination half-life was 19.5 hours for the female group as compared to 23.4 hours for the male group. At steady state, the dose were similar (17.5 hours vs. 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the C_{max} or T_{max} across genders.

Hepatic Impairment

Following a single 15 mg dose of meloxicam there was no marked difference in plasma concentrations in patients with mild (Child-Pugh Class I) or moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein binding of meloxicam was not affected by hepatic impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)]

Renal Impairment

Meloxicam pharmacokinetics have been investigated in subjects with mild and moderate renal impairment. Total drug plasma concentrations of meloxicam decreased and total clearance of meloxicam increased with the degree of renal impairment with this free AUC values were similar in all groups. The higher meloxicam clearance in subjects with renal impairment may be due to increased fraction of unchanged meloxicam which is available for hepatic metabolism and subsequent excretion. No dosage adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been adequately studied. The use of meloxicam in subjects with severe renal impairment is not recommended [see Dosage and Administration (2.5), Warnings and Precautions (5.6) and Use in Specific Populations (8.7)]

Hemodialysis

Following a single dose of meloxicam, the free C_{max} plasma concentration were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis did not lower the total drug concentration in plasma. Therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable [see Dosage and Administration (2.1) and Use in Specific Populations (8.7)].

Drug Interactions Studies

Aspirin: When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. When meloxicam is administered with aspirin (1000 mg three times daily) to healthy volunteers, it tended to increase the AUC (10%) and C_{max} (24%) of meloxicam. The clinical significance of this interaction is not known. See Table 2 for clinically significant drug interactions of NSAIDs with aspirin [see Drug Interactions (7)].

Cholinergic: Pretreatment for four days with cholinergic significantly increased the clearance of meloxicam 50%. This resulted in a decrease in $t_{1/2}$ from 19.2 hours to 12.5 hours, and a 37% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The clinical relevance of this interaction has not been established.

Cimetidine: Concurrent administration of 200 mg cimetidine four times daily did not alter the single-dose pharmacokinetics of 30 mg meloxicam.

Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after ^{14}C -digoxin administration for 7 days at clinical doses. *In vitro* testing found no protein binding drug interaction between digoxin and meloxicam.

Lithium: In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 25% in subjects receiving lithium doses ranging from 60 to 1072 mg twice daily with meloxicam 15 mg QD every day as compared to subjects receiving lithium alone [see Drug Interactions (7)].

Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate administered weekly. Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. *In vitro*, methotrexate did not displace meloxicam from its human serum binding sites [see Drug Interactions (7)].

Warfarin: The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin at doses as low as International Normalized Ratio (INR) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering meloxicam with warfarin since patients on warfarin experience a change in INR and an increased risk of bleeding complication when a new medication is introduced [see Drug Interactions (7)].

11 NONCLINICAL TOXICOLOGY

11.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

There was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice (P28 weeks) administered meloxicam oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in mice (up to 0.5- and 2.6 times, respectively, the maximum recommended human dose [MRHD] of 15 mg/day meloxicam based on body surface area [BSA] comparison).

Mutagenesis

Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome aberration assay with human lymphocytes and in a sister chromatid exchange assay in mouse bone marrow.

Impairment of Fertility

Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 5.8- and 3.2 times greater, respectively, than the MRHD based on BSA comparison).

14 CLINICAL STUDIES

14.1 Osteoarthritis and Rheumatoid Arthritis

The use of meloxicam for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, double-blind, controlled trial. Meloxicam (7.5 mg, 7.5 mg, and 15 mg daily) was compared to placebo. The four primary endpoints were investigator's global assessment, patient global assessment, patient pain assessment, and total WOMAC score (a self-administered questionnaire addressing pain, function, and stiffness). Patients on meloxicam 7.5 mg daily and meloxicam 15 mg daily showed significant improvement in each of these endpoints compared with placebo.

The use of meloxicam for the management of signs and symptoms of osteoarthritis was evaluated in six double-blind, active-controlled trials outside the U.S. ranging from 4 weeks to 6 months' duration. In these trials, the efficacy of meloxicam in doses of 7.5 mg/day and 15 mg/day was comparable to placebo, 20 mg/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial.

The use of meloxicam for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving meloxicam 7.5 mg and 15 mg daily showed significant improvement in the primary endpoint compared with placebo. No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose.

14.2 Juvenile Rheumatoid Arthritis (JRA) Polyarticular and Polyarticular Course

The use of meloxicam for the treatment of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older was evaluated in two 12-week, double-blind, parallel-arm, active-controlled trials.

Both studies included three arms: naproxen and two doses of meloxicam. In both studies, meloxicam doses began at 1.0 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum) and were increased to begin at 10 mg/kg/day. One study used these doses throughout the 12-week dosing period, while the other incorporated a titration after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day (22.5 mg maximum) of meloxicam and 15 mg/kg/day of naproxen.

The efficacy analysis used the ACR Pediatric 30 responder definition, a composite of parent and investigator assessments, counts of active joints and items with limited range of motion, and erythrocyte sedimentation rate. The proportion of responders were similar in all three groups in both studies, and no difference was observed between the meloxicam dose groups.

16 HOW SUPPLIED/STORAGE AND HANDLING

Meloxicam tablets, USP 7.5 mg are yellow colored, round, biconvex tablets, debossed with "158" on one side and "C" on the other.

Meloxicam tablets, USP 15 mg are yellow colored, round, flat beveled tablet, debossed with "CPLA" on one side and "159" on the other.

Meloxicam tablets, USP 7.5 mg are available as follows:

NDC 69097-158-07 Bottles of 100

NDC 69097-158-12 Bottles of 500

NDC 69097-158-15 Bottles of 1000

Meloxicam tablets, USP 15 mg are available as follows:

NDC 69097-159-07 Bottles of 100

NDC 69097-159-12 Bottles of 500

NDC 69097-159-15 Bottles of 1000

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep meloxicam tablets in a dry place.

Dispense tablets in a tight container.

Keep this and all medications out of the reach of children.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.

Inform patients, families, or other caregivers of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy.

Cardiovascular Thrombotic Events

Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their healthcare provider immediately [see Warnings and Precautions (5.1)].

Concomitant Bleeding, Ulceration, and Perforation

Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, nausea, and hematemesis to their healthcare provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of GI bleeding [see Warnings and Precautions (5.2)].

Hepatotoxicity

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, instruct patients to stop meloxicam and seek immediate medical therapy [see Warnings and Precautions (5.3)].

Heart Failure and Edema

Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see Warnings and Precautions (5.5)].

Anaphylactic Reactions

Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat), instruct patients to seek immediate emergency help if these occur [see Contraindications (4) and Warnings and Precautions (5.7)].

Serious Skin Reactions

Advise patients to stop meloxicam immediately if they develop any type of rash and to contact their healthcare provider as soon as possible [see Warnings and Precautions (5.9)].

Female Fertility

Advise females of reproductive potential who desire pregnancy that NSAIDs, including meloxicam, may be associated with a reversible delay in ovulation [see Use in Specific Populations (8.3)].

Fetal Toxicity

Inform pregnant women to avoid use of meloxicam and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closure of the fetal ductus arteriosus [see Warnings and Precautions (5.10) and Use in Specific Populations (8.1)].

Avoid Concomitant Use with NSAIDs

Inform patients that the concomitant use of meloxicam with other NSAIDs or salicylates (e.g., difflural, salicylate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [see Warnings and Precautions (2.2) and Drug Interactions (7)]. Advise patients that NSAIDs may be present in "over the counter" medications for treatment of colds, fever, or insomnia. [see NSAIDs and Low-Dose Aspirin]

Inform patients not to use low-dose aspirin concomitantly with meloxicam until they talk to their healthcare provider [see Drug Interactions (7)].

Manufactured by:

Cipla, Ltd.

Karimnagar, India

Manufactured for:

Cipla USA, Inc.

9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156

Revised: 2/2017

Medication Guide for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

What is the most important information I should know about medicines called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)?

NSAIDs can cause serious side effects, including:

- Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase:
 - with increasing doses of NSAIDs,
 - with longer use of NSAIDs.

Do not take NSAIDs right before or after a heart surgery called a "coronary artery bypass graft (CABG)."

Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.

- Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:
 - without taking one,
 - without warning symptoms,
 - but may cause death.

The risk of getting an ulcer or bleeding increases with:

- past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs; or older age
- taking medicines called "corticosteroids," "anticoagulants," "SSRIs," or "SNRIs" or poor health
- increasing doses of NSAIDs or alcohol or liver disease
- longer use of NSAIDs or bleeding problems
- smoking
- drinking alcohol

NSAIDs should only be used:

- exactly as prescribed
- at the lowest dose possible for your treatment
- for the shortest time needed

What are NSAIDs?

NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of discomforts.

Who should not take NSAIDs?

Do not take NSAIDs:

- if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs,
- right before or after heart bypass surgery.

Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you:

- have liver or kidney problems,
- have high blood pressure,
- have asthma,
- are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering

- taking NSAIDs during pregnancy. You should not take NSAIDs after 28 weeks of pregnancy.
- are breastfeeding or plan to breast feed.

Tell your health care provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your health care provider first.

What are the possible side effects of NSAIDs?

NSAIDs can cause serious side effects, including:

- See "What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?"
- new or worse high blood pressure
 - heart failure
 - liver problems including liver failure
 - kidney problems including kidney failure
 - low red blood cells (anemia)
 - life-threatening skin reactions
 - life-threatening allergic reactions
 - Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.

Get emergency help right away if you get any of the following symptoms:

- | | |
|---|----------------------------------|
| • shortness of breath or trouble breathing | • hurred speech |
| • chest pain | • swelling of the face or throat |
| • weakness in one part or side of your body | |

Stop taking your NSAID and call your health care provider right away if you get any of the following symptoms:

- tarry stools
- blood in stool in your bowel movement or it is black
- more tired or weaker than usual
- vomit blood
- diarrhea
- dark or bloody urine
- dizziness
- there is blood in your bowel movement or it is black and sticky like tar
- fainting
- unusual weight gain
- your skin or eyes look yellow
- skin rash or blisters with fever
- indigestion or stomach pain
- swelling of the arms, legs, hands and feet
- See the warnings.

If you take too much of your NSAID, call your health care provider or get medical help right away.

These are not all the possible side effects of NSAIDs. For more information, ask your health care provider or pharmacist about NSAIDs. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Other information about NSAIDs:

- Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.
- Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your health care provider before using over-the-counter NSAIDs for more than 10 days.

General information about the safe and effective use of NSAIDs:

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. Do not share them.

If you would like more information about NSAIDs, talk with your health care provider. You can ask your pharmacist or health care provider for information about NSAIDs that is written for health professionals.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by:

Cipla Ltd.
Kirkland, India
Manufactured for:
Cipla USA, Inc.
9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156

Revised: 2/2017

DRUG: MELOXICAM

GENERIC: meloxicam

DOSAGE: TABLET

ADMINISTRATION: ORAL

NDC: 70518-1299-0

NDC: 70518-1299-1

NDC: 70518-1299-2

COLOR: yellow

SHAPE: ROUND

SCORE: No score

SIZE: 8 mm

IMPRIENT: C-158

PACKAGING: 30 in 1 BOTTLE, PLASTIC

PACKAGING: 60 in 1 BOTTLE, PLASTIC

PACKAGING: 90 in 1 BOTTLE, PLASTIC

ACTIVE INGREDIENT(S):

- MELOXICAM 7.5mg in 1

INACTIVE INGREDIENT(S):

- MAGNESIUM STEARATE
- SILICON DIOXIDE
- SODIUM CITRATE

Meloxicam

7.5 mg Tablet

QTY: 30

ID #: C:158

Expires:

NDC #: 70518-1299-00

Shape: Round

LOT #:

Ref #: 69097-0158-07

MFG: Cipla USA, Inc., Miami, FL 33156

RX ONLY

Directions For Use: See Package Insert

Store at 20-25°C (68-77°F); excursions permitted to 15-30°C

(59-86°F) [See USP]

Repackaged by: RemedyRepack Inc., Indiana, PA 15701, 1-724-465-8762



Meloxicam

7.5 mg Tablet

QTY: 60

ID #: C:158

Expires:

NDC #: 70518-1299-01

Shape: Round

LOT #:

Ref #: 69097-0158-07

MFG: Cipla USA, Inc., Miami, FL 33156

RX ONLY

Directions For Use: See Package Insert

Store at 20-25°C (68-77°F); excursions permitted to 15-30°C

(59-86°F) [See USP]

Repackaged by: RemedyRepack Inc., Indiana, PA 15701, 1-724-465-8762



Meloxicam

7.5 mg Tablet

QTY: 90

ID #: C:158

Expires:

NDC #: 70518-1299-02

Shape: Round

LOT #:

Ref #: 69097-0158-07

MFG: Cipla USA, Inc., Miami, FL 33156

RX ONLY

Directions For Use: See Package Insert

Store at 20-25°C (68-77°F); excursions permitted to 15-30°C

(59-86°F) [See USP]

Repackaged by: RemedyRepack Inc., Indiana, PA 15701, 1-724-465-8762



Product Information																	
Product Type	HUMAN PRESCRIPTION DRUG																
Route of Administration	ORAL																
Active Ingredient/Active Moiety	<table border="1"> <thead> <tr> <th>Ingredient Name</th> <th>Rank of Strength</th> <th>Strength</th> </tr> </thead> <tbody> <tr> <td>MELOXICAM (981 V53Q9P30C1) (MELOXICAM - UNHYDRATED)</td> <td>MELOXICAM</td> <td>7.5 mg</td> </tr> </tbody> </table>	Ingredient Name	Rank of Strength	Strength	MELOXICAM (981 V53Q9P30C1) (MELOXICAM - UNHYDRATED)	MELOXICAM	7.5 mg										
Ingredient Name	Rank of Strength	Strength															
MELOXICAM (981 V53Q9P30C1) (MELOXICAM - UNHYDRATED)	MELOXICAM	7.5 mg															
Inactive Ingredients	<table border="1"> <thead> <tr> <th>Ingredient Name</th> <th>Strength</th> </tr> </thead> <tbody> <tr> <td>MAGNESIUM STEARATE (981 70171600)</td> <td></td> </tr> <tr> <td>SILICON DIOXIDE (981 411761810)</td> <td></td> </tr> <tr> <td>SODIUM CITRATE (981 92112100)</td> <td></td> </tr> </tbody> </table>	Ingredient Name	Strength	MAGNESIUM STEARATE (981 70171600)		SILICON DIOXIDE (981 411761810)		SODIUM CITRATE (981 92112100)									
Ingredient Name	Strength																
MAGNESIUM STEARATE (981 70171600)																	
SILICON DIOXIDE (981 411761810)																	
SODIUM CITRATE (981 92112100)																	
Product Characteristics	<table border="1"> <thead> <tr> <th>Color</th> <th>Shape</th> <th>Score</th> <th>Imprint</th> </tr> </thead> <tbody> <tr> <td>Yellow</td> <td>Round</td> <td></td> <td>C-158</td> </tr> </tbody> </table>	Color	Shape	Score	Imprint	Yellow	Round		C-158								
Color	Shape	Score	Imprint														
Yellow	Round		C-158														
Packaging	<table border="1"> <thead> <tr> <th>NDC Code</th> <th>Package Description</th> <th>Marketing Start Date</th> <th>Marketing End Date</th> </tr> </thead> <tbody> <tr> <td>70518-1299-00</td> <td>30 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product</td> <td>07-02-2016</td> <td></td> </tr> <tr> <td>70518-1299-01</td> <td>60 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product</td> <td>08-08-2016</td> <td></td> </tr> <tr> <td>70518-1299-02</td> <td>90 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product</td> <td>08-08-2016</td> <td></td> </tr> </tbody> </table>	NDC Code	Package Description	Marketing Start Date	Marketing End Date	70518-1299-00	30 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product	07-02-2016		70518-1299-01	60 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product	08-08-2016		70518-1299-02	90 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product	08-08-2016	
NDC Code	Package Description	Marketing Start Date	Marketing End Date														
70518-1299-00	30 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product	07-02-2016															
70518-1299-01	60 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product	08-08-2016															
70518-1299-02	90 in 1 BOTTLE, PLASTIC, Type 0: Not a Combination Product	08-08-2016															
Marketing Information	<table border="1"> <thead> <tr> <th>Marketing Category</th> <th>Application Number or Monograph Citation</th> <th>Marketing Start Date</th> <th>Marketing End Date</th> </tr> </thead> <tbody> <tr> <td>NDA</td> <td>ANDA 7792</td> <td>07-02-2016</td> <td></td> </tr> </tbody> </table>	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	NDA	ANDA 7792	07-02-2016									
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date														
NDA	ANDA 7792	07-02-2016															

Labeler - REMEDYREPACK INC. (83912255)

Revised: 10/2019

REMEDYREPACK INC.